Tejinder Kaur Bhinder

USPTO Granted Patents = 7 (Patent Applications = 3)

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 6.7

ph-index = 1

Forward Citations = 8(Granted Patents)

Company Filing History:

5 out of 230

Glaxosmithkline Intellectual Property Development Limited

Years Active: 2016-2024

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11976113 - Biopharmaceutical compositions comprising nucleic acids encoding IL-5 binding proteins (2024-05-07),

2. 11613571 - Biopharmaceutical compositions comprising antibody variants (2023-03-28),

3. 11078287 - Binding agonist for treatment of neurological and other disorders (2021-08-03),

4. 10787509 - Biopharmaceutical compositions and related methods (2020-09-29),

5. 10221234 - Antigen binding proteins (2019-03-05),

6. 9914781 - Binding agonist for treatment of neurological and other disorders (2018-03-13),

7. 9434716 - Antigen binding proteins (2016-09-06),

Title: Tejinder Kaur Bhinder: Innovator in Biopharmaceuticals

Introduction

Tejinder Kaur Bhinder is a notable inventor based in Stevenage, GB. He has made significant contributions to the field of biopharmaceuticals, holding a total of seven patents. His work primarily focuses on developing compositions for treating interleukin 5 (IL-5) mediated diseases.

Latest Patents

Among his latest patents are "Biopharmaceutical compositions comprising nucleic acids encoding IL-5 binding proteins" and "Biopharmaceutical compositions comprising antibody variants." These patents relate to innovative compositions aimed at treating diseases associated with interleukin 5, showcasing his expertise in the biopharmaceutical domain.

Career Highlights

Tejinder has worked with prominent companies such as GlaxoSmithKline Intellectual Property Development Limited and Glaxo Group Limited. His experience in these organizations has allowed him to contribute to groundbreaking research and development in the biopharmaceutical sector.

Collaborations

Tejinder has collaborated with notable professionals in his field, including Alan Peter Lewis and Steven Grant. These partnerships have further enhanced his work and innovation in biopharmaceutical compositions.

Conclusion

Tejinder Kaur Bhinder is a distinguished inventor whose work in biopharmaceuticals has led to significant advancements in treating IL-5 mediated diseases. His contributions through patents and collaborations reflect his commitment to innovation in the healthcare industry.

This text is generated by artificial intelligence and may not be accurate.